Steven A Lubitz1, Xiaoyan Yin2, Michiel Rienstra2, Renate B Schnabel2, Allan J Walkey2, Jared W Magnani2, Faisal Rahman2, David D McManus2, Thomas M Tadros2, Daniel Levy2, Ramachandran S Vasan2, Martin G Larson2, Patrick T Ellinor2, Emelia J Benjamin2. 1. From Cardiovascular Research Center (S.A.L., P.T.E.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Boston University and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA (X.Y., J.W.M., D.L., R.S.V., M.G.L., E.J.B.); Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands (M.R.); Department of General and Interventional Cardiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany (R.B.S.); Pulmonary Center and Section of Pulmonary and Critical Care Medicine (A.J.W.), Section of Cardiovascular Medicine (J.W.M., R.S.V., E.J.B.), and Section of Preventive Medicine (R.S.V., E.J.B.), Department of Medicine, Boston University School of Medicine, MA; Department of Medicine, Boston University Medical Center, MA (F.R.); Departments of Medicine and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester (D.D.M.); Sutter Medical Group, Sacramento, CA (T.M.T.); Population Sciences Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (D.L.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); and Departments of Biostatistics (M.G.L.) and Epidemiology (E.J.B., R.S.V.), Boston University School of Public Health, MA. slubitz@mgh.harvard.edu. 2. From Cardiovascular Research Center (S.A.L., P.T.E.) and Cardiac Arrhythmia Service (S.A.L., P.T.E.), Massachusetts General Hospital, Boston; Boston University and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA (X.Y., J.W.M., D.L., R.S.V., M.G.L., E.J.B.); Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands (M.R.); Department of General and Interventional Cardiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany (R.B.S.); Pulmonary Center and Section of Pulmonary and Critical Care Medicine (A.J.W.), Section of Cardiovascular Medicine (J.W.M., R.S.V., E.J.B.), and Section of Preventive Medicine (R.S.V., E.J.B.), Department of Medicine, Boston University School of Medicine, MA; Department of Medicine, Boston University Medical Center, MA (F.R.); Departments of Medicine and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester (D.D.M.); Sutter Medical Group, Sacramento, CA (T.M.T.); Population Sciences Branch, National Heart, Lung, and Blood Institute, Bethesda, MD (D.L.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); and Departments of Biostatistics (M.G.L.) and Epidemiology (E.J.B., R.S.V.), Boston University School of Public Health, MA.
Abstract
BACKGROUND: Guidelines have proposed that atrial fibrillation (AF) can occur as an isolated event, particularly when precipitated by a secondary, or reversible, condition. However, knowledge of long-term AF outcomes after diagnosis during a secondary precipitant is limited. METHODS AND RESULTS: In 1409 Framingham Heart Study participants with new-onset AF, we examined associations between first-detected AF episodes occurring with and without a secondary precipitant and both long-term AF recurrence and morbidity. We selected secondary precipitants based on guidelines (surgery, infection, acute myocardial infarction, thyrotoxicosis, acute alcohol consumption, acute pericardial disease, pulmonary embolism, or other acute pulmonary disease). Among 439 patients (31%) with AF diagnosed during a secondary precipitant, cardiothoracic surgery (n=131 [30%]), infection (n=102 [23%]), noncardiothoracic surgery (n=87 [20%]), and acute myocardial infarction (n=78 [18%]) were most common. AF recurred in 544 of 846 eligible individuals without permanent AF (5-, 10-, and 15-year recurrences of 42%, 56%, and 62% with versus 59%, 69%, and 71% without secondary precipitants; multivariable-adjusted hazard ratio, 0.65 [95% confidence interval, 0.54-0.78]). Stroke risk (n=209/1262 at risk; hazard ratio, 1.13 [95% confidence interval, 0.82-1.57]) and mortality (n=1098/1409 at risk; hazard ratio, 1.00 [95% confidence interval, 0.87-1.15]) were similar between those with and without secondary precipitants, although heart failure risk was reduced (n=294/1107 at risk; hazard ratio, 0.74 [95% confidence interval, 0.56-0.97]). CONCLUSIONS: AF recurs in most individuals, including those diagnosed with secondary precipitants. Long-term AF-related stroke and mortality risks were similar between individuals with and without secondary AF precipitants. Future studies may determine whether increased arrhythmia surveillance or adherence to general AF management principles in patients with reversible AF precipitants will reduce morbidity.
BACKGROUND: Guidelines have proposed that atrial fibrillation (AF) can occur as an isolated event, particularly when precipitated by a secondary, or reversible, condition. However, knowledge of long-term AF outcomes after diagnosis during a secondary precipitant is limited. METHODS AND RESULTS: In 1409 Framingham Heart Study participants with new-onset AF, we examined associations between first-detected AF episodes occurring with and without a secondary precipitant and both long-term AF recurrence and morbidity. We selected secondary precipitants based on guidelines (surgery, infection, acute myocardial infarction, thyrotoxicosis, acute alcohol consumption, acute pericardial disease, pulmonary embolism, or other acute pulmonary disease). Among 439 patients (31%) with AF diagnosed during a secondary precipitant, cardiothoracic surgery (n=131 [30%]), infection (n=102 [23%]), noncardiothoracic surgery (n=87 [20%]), and acute myocardial infarction (n=78 [18%]) were most common. AF recurred in 544 of 846 eligible individuals without permanent AF (5-, 10-, and 15-year recurrences of 42%, 56%, and 62% with versus 59%, 69%, and 71% without secondary precipitants; multivariable-adjusted hazard ratio, 0.65 [95% confidence interval, 0.54-0.78]). Stroke risk (n=209/1262 at risk; hazard ratio, 1.13 [95% confidence interval, 0.82-1.57]) and mortality (n=1098/1409 at risk; hazard ratio, 1.00 [95% confidence interval, 0.87-1.15]) were similar between those with and without secondary precipitants, although heart failure risk was reduced (n=294/1107 at risk; hazard ratio, 0.74 [95% confidence interval, 0.56-0.97]). CONCLUSIONS: AF recurs in most individuals, including those diagnosed with secondary precipitants. Long-term AF-related stroke and mortality risks were similar between individuals with and without secondary AF precipitants. Future studies may determine whether increased arrhythmia surveillance or adherence to general AF management principles in patients with reversible AF precipitants will reduce morbidity.
Authors: P R Kowey; D Stebbins; L Igidbashian; S M Goldman; F P Sutter; S J Rials; R A Marinchak Journal: Pacing Clin Electrophysiol Date: 2001-02 Impact factor: 1.976
Authors: Patricia Jabre; Xavier Jouven; Frédéric Adnet; Gabriel Thabut; Suzette J Bielinski; Susan A Weston; Véronique L Roger Journal: Circulation Date: 2011-05-02 Impact factor: 29.690
Authors: Joseph P Mathew; Manuel L Fontes; Iulia C Tudor; James Ramsay; Peter Duke; C David Mazer; Paul G Barash; Ping H Hsu; Dennis T Mangano Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: S L Kopecky; B J Gersh; M D McGoon; J P Whisnant; D R Holmes; D M Ilstrup; R L Frye Journal: N Engl J Med Date: 1987-09-10 Impact factor: 91.245
Authors: Thomas J Wang; Joseph M Massaro; Daniel Levy; Ramachandran S Vasan; Philip A Wolf; Ralph B D'Agostino; Martin G Larson; William B Kannel; Emelia J Benjamin Journal: JAMA Date: 2003-08-27 Impact factor: 56.272
Authors: Carsten W Israel; Gerian Grönefeld; Joachim R Ehrlich; Yi-Gang Li; Stefan H Hohnloser Journal: J Am Coll Cardiol Date: 2004-01-07 Impact factor: 24.094
Authors: Simon C Body; Charles D Collard; Stanton K Shernan; Amanda A Fox; Kuang-Yu Liu; Marylyn D Ritchie; Tjörvi E Perry; Jochen D Muehlschlegel; Sary Aranki; Brian S Donahue; Mias Pretorius; Juan-Carlos Estrada; Patrick T Ellinor; Christopher Newton-Cheh; Christine E Seidman; J G Seidman; Daniel S Herman; Peter Lichtner; Thomas Meitinger; Arne Pfeufer; Stefan Kääb; Nancy J Brown; Dan M Roden; Dawood Darbar Journal: Circ Cardiovasc Genet Date: 2009-08-02
Authors: William F McIntyre; Pablo A Mendoza; Emilie P Belley-Côté; Richard P Whitlock; Kevin J Um; Natalie Maystrenko; P J Devereaux; David Conen; Jorge A Wong; Stuart J Connolly; Jeff S Healey Journal: Clin Cardiol Date: 2018-10-18 Impact factor: 2.882
Authors: Michele Di Mauro; Antonio M Calafiore; Antonino Di Franco; Francesco Nicolini; Francesco Formica; Roberto Scrofani; Carlo Antona; Antonio Messina; Giovanni Troise; Giovanni Mariscalco; Cesare Beghi; Michele De Bonis; Cinzia Trumello; Antonio Miceli; Mattia Glauber; Marco Ranucci; Carlo De Vincentiis; Mario Gaudino; Roberto Lorusso Journal: Int J Cardiol Date: 2020-10-04 Impact factor: 4.164